血管压缩剂启动的时间与感染性休克患者的死亡率增加无关
Lauren Page Black1, Charlotte Hopson2, Michael A Puskarich3
1Department of Emergency Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL.
Annals of emergency medicine
|November 4, 2025
概括
在性休克中迅速启动血管压缩剂在本研究中没有影响90天的死亡率. 这一发现表明,在败血症休克管理中,其他因素对患者的生存更为关键.
科学领域:
- 关键护理医学 关键护理医学
- 流行病学 流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在性休克患者中,开始血管压缩剂治疗的最佳时间是一个关键但尚未解决的临床问题.
- 早期的血管压缩剂通常被认为可以改善结果,但缺乏强有力的证据.
研究的目的:
- 在一大批败血症休克患者中,调查血管压缩剂启动时间和90天死亡率之间的关联.
- 为了确定其他独立的预测者在败血症休克死亡率.
主要方法:
- 使用OneFlorida数据信任,全州范围的医疗保健数据库的回顾性队列研究.
- 纳入标准:患有败血性休克,低血压和败血症或感染的患者,接受抗生素治疗.
- 主要结局:90天死亡率,分析使用多变量逻辑回归与LASSO变量选择.
主要成果:
- 总共分析了4,699名患有败血性休克的患者 (2012-2018).
- 90天死亡率为34%. 开始血管压缩剂的时间与90天死亡率没有显著关联 (OR 1.01,95% CI 1.00-1.02).
- 死亡率的独立预测因素包括年龄,机械呼吸,SOFA分数组件,乳酸,慢性高血压和肝病.
结论:
- 在这个大队列中,从第一个低血压事件到血管压缩剂启动的时间与90天死亡率无关.
- 血管压缩剂启动的时间没有影响血管压缩剂免费的日子.
- 诸如年龄,通风状态,器官功能障碍和并发症等因素是感染性休克结果的更重要的预测因素.
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
635
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
635
01:23Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
01:22Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:24Blood Pressure Imbalances and Circulatory Shock
1.5K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K